SCLERO.ORG
Search
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Autoimmune
Media Stories
Scleroderma
ISN/Website
Scleroderma Archive
We maintain news archives for the most recent 3 years.
2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2019 - 2018 - 2017 - 2016

June 2018 Scleroderma News

Cardiac involvement in undifferentiated connective tissue disease (UCTD) at risk for systemic sclerosis (SSc) (otherwise referred to as very early–early systemic sclerosis): a TDI study. Our study shows that UCTD–risk–SSc patients show a previously unrecognized, mild biventricular systolic and diastolic dysfunction as compared to controls. PubMed, Clin Exp Med, 2018 May;18(2):237-243. (Also see Undifferentiated Connective Tissue Disease)

Microbial and metabolic multi–omic correlations in systemic sclerosis (SSc) patients. Our data suggest that in SSc, intestinal microbiota is characterized by proinflammatory alterations subtly entwined with the metabolic state. PubMed, Ann N Y Acad Sci, 05/11/2018. (Also see Bowel Dysfunction)

Effects of autonomic dysfunction (AD) on exercise tolerance in systemic sclerosis (SSc) patients without clinical and instrumental evidence of cardiac and pulmonary involvement. In SSc patients without cardiopulmonary involvement AD is associated with better exercise tolerance and cardiac function during physical effort. PubMed, Clin Exp Rheumatol, 05/04/2018. (Also see Brain Involvement and Cardiac (Heart) Involvement)

Challenges and strategies for coping with scleroderma: implications for a scleroderma–specific self–management program. Although the challenges experienced by patients with scleroderma are unique, findings from this study might help better understand patients' perspectives regarding coping and disease management for other chronic diseases as well. PubMed, Disabil Rehabil, 2018 May 9:1-10. (Also see Coping Strategies)

Acute and chronic effects of two different intravenous iloprost (ILO) regimens in systemic sclerosis: a pragmatic non–randomized trial. ILO had an acute effect as assessed by power Doppler US and by contrast, an ILO chronic effect was not detectable before the following infusion in both treatment groups. PubMed, Rheumatology (Oxford), 05/03/2018. (Also see Inhaled Prostacyclin)

Prognostic Factors of Renal Involvement in Systemic Sclerosis (SSc). In SSc patients, a periodic follow–up based on clinical and laboratory evaluation, colorDoppler ultrasound and, in some cases, renal biopsy is required to evaluate renal involvement. PubMed, Kidney Blood Press Res, 2018 May 10;43(3):682-689. (Also see Kidney (Renal) Involvement)

Anti–endothelial cell antibodies (AECA) do not correlate with disease activity in systemic sclerosis (Ssc). AECA are not associated with the activity of SSc, although the presence of AECA might be an indicator of vascular complications development in Ssc. PubMed, Postepy Dermatol Alergol, 2018 Apr;35(2):185-191. (Also see Antibodies)

Methyl-CpG-binding protein 2 (MeCP2) mediates antifibrotic effects in scleroderma (SSc) fibroblasts. This study demonstrates a novel role for MeCP2 in skin fibrosis and identifies MeCP2-regulated genes, which can be potentially targeted for therapy in SSc. PubMed, Ann Rheum Dis, 05/14/2018. (Also see Fibroblasts and Skin Fibrosis)

Lenabasum Safe and Effective in Diffuse Scleroderma Patients, One–year Trial Data Show. Lenabasum, by Corbus Pharmaceuticals, was shown to be safe, well-tolerated and of benefit to patients treated for one year in a long-term extension of a Phase 2 trial. Scleroderma News, 05/17/2018. (Also see Clinical Trials and Endocannabinoid System)

Long–term Outcomes in Systemic Sclerosis Associated Pulmonary Arterial Hypertension PAH) from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS). PAH accounted for more than half of deaths and primarily within the first few years after PAH diagnosis. PubMed, Chest, 05/16/2018. (Also see Prognosis of Pulmonary Hypertension)

Go to Scleroderma Medical News: May 2018
 

We have the world's best supporters! See ISN News.

 

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected]. Disclaimer. Privacy Policy.
 

The most important thing in the world to know about scleroderma is sclero.org!